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We thank Tarabichi and colleagues for the constructive criticism of our Williams et al. 20161 work. 
Their critique has four main points that we address below. 
 
1. Impact of clonal copy number alterations 
 
In Williams et al. 2016
1
, we assessed the cumulative variant allele frequency (VAF) distribution 
M(f) over the frequency range f=[0.12,0.24] to restrict our analysis to subclonal variants within a 
range applicable to the diverse datasets we considered. Tarabichi and colleagues note that 
tumours with a tetraploid genome will have an additional ‘peak’ of clonal mutations at f~0.25 
(mutations in a single allele, Supplementary Figure 1A), thus causing incorrect rejection of 
neutrality (Supplementary Figure 1B). The integration range that we chose was based on a triploid 
tumour with read depth of 100X, giving an upper threshold of 0.26 (see Supplementary Methods). 
Although this is suitable for most cases, it is not for a tetraploid tumour, suggesting that the number 
of tumours consistent with neutral evolution could be larger than we reported. In Supplementary 
Figure 1C we show how this problem can be avoided by adjusting the range for tetraploid tumours.  
 
We do acknowledge that the 1/f integration method is more accurate when applied to the whole 
VAF spectrum of subclonal mutations only. Moreover, we have recently developed a Bayesian 
model selection framework that compares the neutral model against models with selection, using 
the entire VAF distribution2. We care to stress however, that the majority of cancers analysed in 
our original manuscript were not neutral, and showed signs of subclonal selection. 
 
 2. Interpretation of the 1/f statistical test 
 
Tarabachi and colleagues correctly note that failing to reject the null is not necessarily evidence for 
it. While this is true, hypothesis-driven evolutionary analysis of cancer genomic data requires a 
sensible null. Analysing data without knowing what to expect in the simplest scenarios may lead to 
wrong conclusions, as we have highlighted
3
. We have proposed neutrality, the null model of 
molecular evolution4, as a sufficient explanation of the available data from a proportion of tumours. 
The test we applied quantifies the deviation from the null distribution in terms of a change in the 
model parameter (s=0 vs s>0). This structure arises from a frequentist approach and arguments 
for setting up the test in any other way are arbitrary and impractical. There are an infinite number 
of models of selection, some producing vanishingly small and so unmeasurable deviations from 
neutrality (e.g. weak selection), while others are biologically unrealistic (e.g. every mutation is a 
driver, constant population size in cancer). This is why in molecular evolution neutrality is a 
suitable null
4
. In our view, selection is arguably the most important force in cancer, but a sensible 
null model avoids over-interpreting data. 
 
Tarabichi and colleagues state that the M(f)~1/f deterministic solution we reported in our 
manuscript (Eq.7) relies on the strong assumption of synchronous cell divisions. That is not the 
case: Eq.7 is the convergent solution of a continuous-time stochastic branching process for large 
number of cells
5
. Simulations based on Gillespie algorithm that explicitly model asynchronous cell 
divisions agree with the solutions of the stochastic branching process. Tarabichi et al. also state 
that simulating stochastic processes is more realistic. This is indeed what we did in our original 
manuscript (Fig S9-S11 in Williams et al. 2016), demonstrating the convergence to the 
deterministic solution. A comprehensive analysis of the underlying stochastic Luria-Delbrück model 
shows that the scaling behaviour of the stochastic branching process (1/f tail) remains unchanged 
even in the explicit presence of stochastic cell death
6
. In Tarabichi’s letter Figure 1b, the claim that 
a stochastic neutral model does not imply 1/f is therefore incorrect, as also demonstrated by others 
before us
5-7
. Moreover, in the beginning of their letter Tarabachi and colleagues argue that the 1/f 
tail is solely due to drift. This is true only in populations of constant size. In exponentially growing 
populations that start from a single cell such as cancer, the 1/f subclonal tail emerges instead from 
somatic mutations acquired at different times during growth. 
 
3. Insights from simulated tumours 
 
Tarabichi and colleagues use a stochastic branching process, similar to our previous 
implementation1,2, to generate synthetic genomic data and test our method. In their Figure 1, 
Tarabichi et al. present a synthetic analysis of the 1/f test using the analytical deterministic solution 
(Figure 1A) and stochastic simulations (Figure 1B). In both analyses, a new subclone is introduced 
 at a certain fixed time point. First, we note that Tarabichi’s Figure 1a is different from 1b, which 
contradicts mathematical theory
1,5-8
.   
 
The parameters used in Tarabachi‘s simulations are also rather extreme. In their model the 
emergence of a subclonal driver increases the net-growth rate (advsubclone, selective advantage), 
and modifies the mutation rate at the same time. Curiously, the mutation rate can decrease by a 
factor of 8, or increase by a factor 100. A rate of 1024 new mutations per cell division (Tarabichi’s 
Figure 1a, x-axis, 𝜇𝑠𝑢𝑏𝑐𝑙𝑜𝑛𝑒=2
10) pertains only to a very small set of colorectal and uterine cancers 
with POLE/POLD mutations. A POLE subclone arising within a POLE wild-type background is a 
very rare event9. Thus, we urge caution when considering the implications of the parameters at the 
extremities of the range considered by Tarabichi et al.    
 
To address the authors’ criticism, we have reproduced their Figure 1b with our stochastic 
branching process (Figure 1A, see Supplementary Methods). We systematically found that when a 
subclone with fsubclone≥10% is selected (selective advantage 𝑎𝑑𝑣𝑠𝑢𝑏𝑐𝑙𝑜𝑛𝑒 > 0.5), the 1/f test identifies 
it correctly (neutrality is rejected; top left quadrant of Figure 1A, example in 1B). When the new 
subclone is instead very small (weak selection), the 1/f test fails to reject neutrality (𝑎𝑑𝑣𝑠𝑢𝑏𝑐𝑙𝑜𝑛𝑒 <
0.5, bottom half of Figure 1A, example in 1C). Figure 1D illustrates the relationship between the 
selective advantage and the subclone cell fraction in the final tumour, highlighting the issue of the 
limit of detectability (LOD). We have subsequently quantified this effect2, identifying a ‘wedge of 
selection’ that describes the detectability problem in cancer genomic data at current resolution. If 
subclonal selection does not significantly change the clonal composition of the tumour, the 
signature of neutral growth (‘1/f tail’) will still dominate the detectable VAF spectrum (bottom part of 
Figure 1A).  
 
Notably, for a hypermutant subclone with strong selective advantage (𝜇𝑠𝑢𝑏𝑐𝑙𝑜𝑛𝑒64, top right-hand 
side of Figure 1A,), the analysis showed a massive 1/f tail containing thousands of the subclone’s 
private mutations. These mutations dominate the entire VAF distribution and obscure the 
underlying subclonal structure (Figure 1A, example in 1E). It is not surprising that our test, or any 
other test, would struggle to detect any subclonal cluster or deviation from 1/f in these cases. 
Curiously, for moderate values of selection (advsubclone~0.5), a change in mutation rate from normal 
to hypermutant could be detected, leading to rejection of neutrality (mid-right area in Figure 1A, 
example in 1F, see also Fig S11H in Williams et al. 2016). For weak selection and a hypermutator 
subclone, the new subclone did not reach a detectable size and therefore neutrality could not be 
rejected (Figure 1C).  
 
Importantly, we note that the lack of discriminatory power in these peculiar scenarios does not 
depend on our method but it is largely due to minimal signal in the data. To demonstrate this, we 
 compare our method with the extended integration range (Figure 1G) to DPclust, a method to 
detect subclones based on Dirichlet Process clustering10 proposed by some of the authors of the 
letter (see Supplementary Methods). Even under optimal circumstances (strong selection), the 
sensitivity of DPclust is suboptimal in the vast majority of cases (Figure 1H).  
 
We are pleased however that Tarabichi and colleagues confirmed that 1/f tails are pervasive in 
cancer genomic data. Neutral tails are a simple consequence of clonal growth, and appear within 
each individual clone during its expansion
1,2
. 
 
4. Analysis of subclonal selection using dN/dS ratios 
 
Using a test inspired by the classical dN/dS method, Tarabichi et al. argue to find evidence of 
subclonal selection in tumors classified by our test as neutral. Specifically, the authors pool 
together subclonal mutations in known cancer genes from multiple patients, and calculate a dN/dS 
value for neutral and non-neutral groups. Their criticism is that subclonal mutations in the neutral 
group should lack evidence of selection (dN/dS~1).  
 
First, we note that it is wrong to draw conclusions about individual samples from such a population-
level statistic. Instead, discrepancies between the dN/dS value and our 1/f test results could simply 
mean that our method may have misclassified one, or more, patients. To investigate this, we 
reproduced their analysis using the same dN/dS method11 and measured global dN/dS for 369 
driver genes11 in colorectal and gastric cancers analysed in our original manuscript1. Tarabichi’s 
TCGA pan-cancer analysis used CAVEMAN calls that are not publicly available, so instead we 
reanalysed the pan-cancer TCGA variant calls publicly available from the GDC data portal (see 
Supplementary Methods). We found that in all three cohorts, dN/dS of subclonal missense 
mutations in neutral-classified tumours was not significantly different from 1, thus confirming our 
findings (Figure 2A-C, missense mutations on the left, blue bars).  
 
Interestingly, we found a small group of neutrally classified patients with an unusually high number 
of subclonal nonsense mutations in putative driver genes. 1/57 gastric cases (1.7%) and 11/290 
(3.8%) of pan-cancer cases had 3 or more subclonal nonsense mutations. We manually examined 
these patients (Supplementary Figure 2) and found that these were affected by clonal mutations 
‘bleeding’ into the subclonal integration range, misclassification caused by ploidy measurement 
errors, and possibly the presence of selected subclones hidden underneath 1/f tails. We care to 
stress that these tumours had been classified with our original limited integration range. After 
removing patients with 3 or more nonsense mutations (e.g. leaving 96.2% of putatively neutral 
cases in the pan-cancer cohort), the dN/dS value for nonsense was not significantly different from 
the neutral background (Figure 2C, dN/dS=1.44, p=0.32). We demonstrate this by generating 
 dN/dS values for ‘control sets’ (background) of passenger genes using bootstrapping of 1,000 
random sets of 198 non-driver genes12 as well as neutral genes (Figure 2D). This analysis 
indicates a systematic positive bias for the estimation of dN/dS. This could be due to public GDC 
calls being depleted of synonymous somatic mutations present in dbSNP, skewing dN/dS values 
as mentioned in Martincorena et al. 2017. Interestingly, subclonal dN/dS values were consistently 
higher in non-neutral versus neutral cases, although this was not significant (Figure 2D). 
 
We care to highlight that dN/dS analysis at the cohort-level combines mutations from different 
patients, whereas the neutrality test is patient-specific. Even a single misclassified patient carrying 
multiple nonsense mutations in driver genes significantly alters the dN/dS value of a whole cohort. 
While dN/dS can reveal an excess or depletion of mutations in a cohort, Tarabichi et al’s analysis 
cannot differentiate whether this is coming from one or multiple patients. 
 
Summary 
 
We thank Tarabachi and colleagues for providing some valid constructive criticism of our original 
manuscript.  In our assessment of their critique however, our original conclusion remains valid: that 
neutral evolution provides an entirely adequate description of the pattern of intra-tumour 
heterogeneity that has been observed to date across many tumours. We are also grateful to 
Tarabichi and co-authors because they led us to the finding that VAF distribution analyses applied 
to single patients, like our neutrality test, can be carefully combined with cohort-level statistics like 
dN/dS to increase the power to discriminate between neutral dynamics and selection in cancer. 
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 Figure 1. Insights from stochastic simulations of cancer growth. (A) Heatmap recapitulating 
Tarabichi’s Figure 1b with same parameter set and showing proportion of simulations where 
neutrality was rejected (200 cases per parameter combination). (B) Example VAF distribution with 
a detectable subclonal cluster (dashed line indicates subclone frequency). The 1/f test rejects 
neutrality in favour of selection (R2 reported). (C) Example VAF distribution with a weakly-selected 
subclone that remains below the limit of detection (100X depth). (D) Subclone cell fraction in the 
final tumour as a function of fitness advantage, for advsubclone<0.5 the subclone rarely reaches 
detectable size of ~10% cell fraction (assuming 100x depth). (E) Example VAF distribution for a 
subclone with selective advantage and, at the same time, high mutation rate. (F) Example VAF 
distribution for a selected and extreme mutator subclone. (G) Sensitivity of the 1/f test applied to 
subclonal mutations in the extended range of VAF=[0.025,0.45] from the simulations in panel A, 
numbers report proportion of cases where neutrality was rejected (R2<0.98). (H) Sensitivity of 
subclone detection of DPclust, a Dirichlet subclonal clustering method, when applied to the same 
simulated data. Numbers report proportion of cases (20 cases per combination) where the correct 
subclone has been identified within a 5% CCF error with respect to true position.  
 
 
 
Figure 2. Detecting subclonal selection with dN/dS analysis. dN/dS analysis using 
Martincorena et al. 2017 method applied to colorectal cancers (A), gastric cancers from ref
13
 
analysed in Williams et al. 2016 (B), and TCGA pan-cancer cases using newly available GDC calls 
to reproduce Tarabichi’s dN/dS analysis (C). Cancers were classified as neutral or non-neutral 
using the 1/f test, and the dN/dS values of were calculated over pooled variants from each group 
 (split between clonal/subclonal and missense/nonsense). (D) Comparison of the dN/dS estimates 
obtained for the 198 driver genes (black dot: point estimate, error bars: 95% CI) with the 
distribution of 1,000 random subsets from three control sets of non-driver genes demonstrates a 
general positive bias of estimated dN/dS values (white dot: median, box: interquartile range, 
whiskers: 90% prediction interval). After removing 3.8% of pan-cancer cases with 3 subclonal 
nonsense mutations in driver genes, both missense and nonsense dN/dS in neutral cancers were 
not significantly different from the neutral expectation. 
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